Funding vs FDA Actions
Side-by-side coverage analysis for Funding and FDA Actions.
This comparison applies the same classification pipeline used across every story on this site, which scores each linked entity at a minimum 35 percent relevance threshold before it is surfaced. According to our editorial methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
Funding
Biotech venture funding, grants
- Stories
- 60
- Avg Impact
- 6/10
- Dominant Tone
- Neutral
- Latest
- 1d ago
FDA Actions
Approvals, rejections, priority reviews
- Stories
- 73
- Avg Impact
- 6.6/10
- Dominant Tone
- Positive
- Latest
- 2d ago
Recent Headlines
Funding
- 35 Flagged Efforts: Dual-Use AI in Gain-of-Function Research
- Jupiter's $2M Direct Offering: A Signal of Biotech Cash Strain
- Ampol's LCLF pivot turns $5B bio-feedstock exports into home market
- Intuitive Bets on 316,000-Sq-Ft Penang Site for Surgical Device Manufacturing
- Moleculin's $4.06M Market Cap vs ($1.40) EPS: Pipeline Survival?
- Nutex swings to $65.8M profit as GLP-1 wave lifts Omada 43%
- Apyx Medical EPS Beats by $0.06, Stock Still Slides 1.8% to $4.38
- ARE Q2 Revenue $662.78M: What Biotech Tenants Should Expect from FY’26 Guidance
- Aureka Biotech Raises $100M Series B for Biological Foundation Models
- $200M Biodiversity Fund Unleashes Biotech’s Role in Saving 100 Species
FDA Actions
- 3 in 5 abortions use mifepristone as 5th Circuit weighs limits
- FDA Drug Chief to Oversee 3 Psychedelic Candidates: Psilocybin, MDMA, LSD
- FDA Names 4 Center Directors as Psychedelics Reviews Take Shape
- Mifepristone in 60% of U.S. abortions faces FDA rule fight in 5th Circuit
- Endometriosis tests advance abroad while U.S. lags for 1 in 10 women
- Rasonque Approved: KRAS Inhibitor Doubles Survival to 13.2 Months
- ICP DAS-BMP TPU with 20-40% Barium Sulfate Targets Implantable Devices
- Druckenmiller's Q2 RYTM Bet Targets 2 FDA Nods in Rare Obesity
- Zeon's FDA FSMA + NSF 21 CFR Part 111 cGMP Boost India CDMO Credibility
- Opdivo's 1/12th Dose Shows Efficacy in Indian Study, Sparking FDA Label Debate